The data suggest that ATGL can be used as a therapeutic target for CRPC, and the main problem is to target the potential effect of ATGL on the heart, which also provides a new perspective for the treatment of prostate cancer metabolism 195. The gene discussed is PNPLA2; the disease is prostate carcinoma.